Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04992780 · ClinicalTrials.gov registry record · Phase 2
Comparing Hypo-fractionated Intensity- Modulated Radiation Therapy to Standard- Fractionated IMRT Along With Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer
A Phase 2 study of Non Small Cell Lung Cancer Stage, sponsored by University of Kansas Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 6
- Study locations
NCT04992780: Recruiting Phase 2 study of Non Small Cell Lung Cancer Stage, sponsored by University of Kansas Medical Center.
NCT04992780 is a Phase 2 study of Non Small Cell Lung Cancer Stage that is actively recruiting participants, run by University of Kansas Medical Center. The registered enrollment target is 50 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower). The trial reports 6 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04992780, a Phase 2 study of Non Small Cell Lung Cancer Stage, is actively recruiting participants, sponsored by University of Kansas Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 6
- Study locations
Study Summary
The hypothesis for this study is that hypofractionated IMRT to 62.5 Gy in 25 fractions (2.5 Gy/fraction) with concurrent carboplatin and paclitaxel, followed by maintenance durvalumab will improve locoregional control at 18 months by 10% compared to standard-fractionated chemo-IMRT/durvalumab. A modest improvement in locoregional control (LRC) was selected as a target which could merit further study of this hypofractionated IMRT regimen in a Phase III trial
Primary Outcome
RECIST 1.1
Conditions Studied
Interventions
- RADIATION Hypo-Fractionation
- RADIATION Standard-Fractionation
Study Locations (6)
Kansas
- The University of Kansas Cancer Center, Westwood Campus - Kansas City
- The University of Kansas Cancer Center, Overland Park Clinic - Overland Park
- KUCC MCA- TUKHS, Saint Francis Hospital - Topeka
Missouri
- The University of Kansas Cancer Center, North Clinic - Kansas City
- The University of Kansas Cancer Center, Lee's Summit Clinic - Lee's Summit
- University of Kansas Cancer Center, North Kansas City Hospital - North Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2022-02-25 |
| Est. Completion | 2026-11 |
| Phase | Phase 2 |
What NCT04992780 shows while recruiting
NCT04992780 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower).
The record links to 1 condition, with Non Small Cell Lung Cancer Stage appearing as the primary indexed condition, and to 2 interventions - of which Hypo-Fractionation is the first listed.
NCT04992780 lists 6 locations in 2 states (Kansas, Missouri).
Frequently Asked Questions
What is clinical trial NCT04992780 about?
NCT04992780 is a clinical study titled "Comparing Hypo-fractionated Intensity- Modulated Radiation Therapy to Standard- Fractionated IMRT Along With Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer". The hypothesis for this study is that hypofractionated IMRT to 62.5 Gy in 25 fractions (2.5 Gy/fraction) with concurrent carboplatin and paclitaxel, followed by maintenance durvalumab will improve locoregional control at 18 months by 10% compared to standard-fractionated chemo-IMRT/durvalumab. A mod...
What is the current status of trial NCT04992780?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2022-02-25. Estimated completion is 2026-11.
What conditions does trial NCT04992780 study?
This clinical trial studies the following conditions: Non Small Cell Lung Cancer Stage.
What interventions are being tested in trial NCT04992780?
The interventions under investigation include: Hypo-Fractionation (RADIATION), Standard-Fractionation (RADIATION).
Who is sponsoring clinical trial NCT04992780?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04992780 being conducted?
This trial has 6 study locations across Kansas, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04992780's enrollment target sits among peer trials
50 1195th of 2000 higher than 741 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI